• Equity PC Ratio   0.57
  • |
  • Index PC Ratio   1.14
  • |
  • Total PC Ratio   0.97
  • |
  • VIX PC Ratio   0.54
  • VIX 13.95
  • VXN 18.04
  • VXO -
  • ISEE 85.00

TruCharts Trading Strategies and Stock Buy/Sell Reports
(Show Details)


Chart Settings
No saved settings found!

Chart Type:
From: / / To: / /
Show detail in :
 Chart Skins:      
Price Overlays:





Indicator Windows:





Company Profile

Acorda Therapeutics, Inc., a biotechnology company, develops therapies for multiple sclerosis, spinal cord injury, and other nervous system disorders. Its marketed products include Ampyra (dalfampridine), a potassium channel blocker for improving walking in patients with multiple sclerosis; and Zanaflex Capsules and Zanaflex tablets (tizanidine hydrochloride), a short-acting drug for the management of spasticity. The company?s pipeline also includes various products in development for the treatment, regeneration, and repair of the spinal cord and brain. Its preclinical products comprise remyelination programs that include two distinct therapeutic approaches to stimulate repair of the damaged myelin sheath in multiple sclerosis, neuregulins/glial growth factor 2, and remyelinating antibodies; and chondroitinase program, which develops second generation approaches to overcoming the proteoglycan matrix. Acorda Therapeutics sells its products through specialty sales force, managed care team, and contract pharmaceutical telesales organizations. The company was founded in 1995 and is based in Hawthorne, New York.

NO
     
ACOR (Acorda Therapeutics Inc)
Last Trade 3.565 Date 9/19/2019
Change % 0.43 % Price Change 0.02
Open 3.56 52 Week High 21.63
High 3.63 52 Week Low 2.27
Low 3.49 Type stock
Volume 60637 Average Volume 1548934
Prev Close 3.55 Stock Exchange NASDAQ
Bid 3.55 Ask 3.57
Bid Size 3 Ask Size 1
1st Yr Estimated EPS Growth 0.5833 2nd Yr Estimated EPS Growth -0.485
2 Years Forward Earning Yield -0.3859 2 Years Forward PE Ratio
2 Years EV/Forward EBIT 2 Years EV/Forward EBITDA
Book Value per Share 11.3253 Book Value Yield 3.1902
Buy Back Yield CAPE Ratio
Cash Return -0.3885 Cash Flow per Share -0.5579
Cash Flow Yield -0.1572 Dividend Rate
Dividend Yield 5 Year Dividend Yield
Earning Yield -0.4732 EV/EBIT
EV/EBITDA EV / Free Cash Flow
EV / Forward EBIT EV / Forward EBITDA
EV / Forward Revenue 1.4247 EV / Pre Tax Income
EV / Revenue 0.7548 EV / Total Asset 0.193
Expected Dividend Growth Rate Free Cash Flow per Share -2.2436
Free Caash Flow Ratio Free Cash Flow Yield -0.632
Forward Calculation Style Forward Dividend Yield
Forward Earning Yield -0.7493 Forward PE Ratio
Forward Return on Asset Forward Return on Equity
Normalized PE Ratio Payout Ratio 0.0
PB Ratio 0.313458 PB Ratio 10 Year Growth -0.248079
PB Ratio 3 Year Growth 1.466807 Cash Ratio 3 Year Average 438.5358
Price to Cash Flow Ratio PEG Payback
PEG Ratio PE Ratio
PE Ratio 10 Year Average PE Ratio 10 Year Growth
PE Ratio 10 Year High PE Ratio 10 Year Low
PE Ratio 1 Year Avg PE Ratio 1 Year High
PE Ratio 1 Year Low PE Ratio 3 Year Avg 18.442997
PE Ratio 5 Year Avg PE Ratio 5 Year High
PE Ratio 5 Year Low Free Cash Flow Ratio 10 Year Growth
Free Cash Flow Ratio 3 Year Avg 16.781626 Price Change 1 Month 1.099071
Price to Cash Ratio 0.575242 Price / EBITDA
Price to Sales Ratio 0.551871 Price to Sales Ratio 10 Year Growth -0.29541
Price to Sales Ratio 3 Year Avg 1.667466 Price to Sales Ratio 5 Year Avg
Sale per Share 6.4327 Sales Yield 1.812
Sustainable Growth Rate -0.1379 Tangible Book Value per Share -3.2142
Tangible Book Value per Share 3 year Avg -5.7026 Tangible Book Value per Share 5 year Avg -1.1906
Total Asset per Share 24.8911 Total Yield
Working Capital per Share 5.4964 Working Capital per Share 3 Year Avg 5.1535
Working Capital per Share 5 Year Avg 8.2057 Beta 1.583013